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2. List.all additions and deletions in professional personnel and any changes in effort. 
• 3. Progress Report. (See Instructions) 
la. "Inhibitors of Elastase and Pulmonary Emphysema," James C. Powers, Trends  
in Biochemical Sciences, 1, 211 (1976). 
lb. "Specificity of Porcine Elastase, Human Leukocyte Elastase and Cathepsin 
G. Inhibition with Peptide Chloromethyl Ketones," Biochem. Biophys. Acta, 
in press. 
"Haloketone Inhibitors of Proteolytic Enzymes," James C. Powers, Chap. in 
Weinstein (ed.), "Chemistry and Biochemistry of,Amino Acids, Peptides and 
Proteins," Vol. 4, Marcel Dekker, New York, in press. 
"Reaction of Serine Proteases with Halomethyl Ketones," James C. Powers, 
Chap. in W. Jakoby and M. Weilchek (eds.), Meth. in Enzymology, Academic 
Press, in press. 
"Reaction of Serine Proteases with Aza-Amino Acid and Aza-peptide Derivatives," 
James C. Powers and B. F. Lupton, Chap. in W. Jakoby and M. Weilchek (eds.), 
Meth. in Enzymology, Academic Press, in press. 
2. Dr. M. Sakamoto has returned to Japan after spending one year in my laboratory. 
He is an assistant professor at Meiji College of Pharmacy, Tokyo, Japan, 
who spent his sabbatical leave doing research on synthetic protease inhibitors. 
No changes in effort are planned. 
3. Progress Report 
Objectives. A number of proteolytic enzymes such as elastase, collagenase 
and cathepsin G have been shown to be involved in diseases such as pulmonary 
emphysema and arthritis which involve tissue destruction. The goal of this 
research is to design and synthesize specific and effective inhibitors 
for these proteolytic enzymes. The inhibitors are proving to be invaluable 
in the study of the normal biological function and the role of these 
proteases in disease. I am hopeful that synthetic protease inhibitors 
will find use in the clinical treatment of pulmonary emphysema and other 
diseases in the near future. 
Elastase and Cathepsin G-Chloromethyl Ketones. Our goals for the year were 
to synthesize a radiolabeled peptide chloromethyl ketone elastase inhibitor, 
a water soluble inhibitor and to stimulate other investigators to carry 
clt animal studies with these inhibitors. We synthesized both [
i4
C] and 




an effective elastase inhibitor. 
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We are also collaborating with Aaron Janoff in a study of the effect of 
the inhibitors on emphysema induced by elastase in rats, and finally we plan 
to use a'labeled chloromethyl ketone to locate the active site histidine of 
leukocyte elastase in collaboration with J. Travis (University of Georgia). 
Elastase--Other Inhibitors. One goal for the current year was to learn how 
to synthesize derivative of a-amino sulfonic acids and devise methods for their 
introduction into peptide structures. We wish to synthesize some sulfonamide 
and sulfonic acid derivatives related to elastase substrates. Very little 
attention has been devoted to this problem during the last year and thus little 
progress has been made. We have learned how to synthesize dipeptide sulfonic 
acids such as Z-Gly-Sala-OH (Sala = 	CH(CHOS0 9-). We have also been able 
to prepare sulfonic acid methyl esters such a§) gly-OCH,'. In the next year 
we plan to continue our efforts to develop synthetic metheids so we can prepare 
compounds such as Ac-Ala-Ala-Sala-OCH
3 
and Ac-Ala-Ala-Sala-F as potential 
elastase inhibitors. However, we do not expect to devote much time to this 
problem next year since we are currently giving other areas of investigation 
higher priority. 






F and shown 
that it inhibits elastase. We are planning to study the kinetics or reaction 
of this inhibitor with elastase and cathepsin G in the course of the next year. 
In the area of aza-peptides, we have synthesized a number of new ..compounds 
and tested them as inhibitors of elastase. These include Ac-Ala-Ala-UCH 
3
- 
NCH,-00-0Np and Ac-Ala-Aala-CH,)NCH 1-00-0Np. The second compound slowly inhibits 
ela3tase (t 1/2 = 1-2 days) while ehe first is not an inhibitor. Thus neither 
compound offers any advantages over our best aza-peptide elastase inhibitor 
.Ac-Ala-Ala-Anvi-ONp. In the future.we would like to make analogs of Ac-Ala-Ala-
Anvl-ONp with different leaving groups besides p-nitrophenol. 
Metalloproteases-Collagenase. During the last year we have made considerable 
progress in the area of metalloprotease inhibitors. Our goal is to develop 
functional groups which would inactivate members of the metalloprotease family 
and then incorporate this functional group into a substrate like structure in 
order to obtain a specific inhibitor for mammalian collagenase. We have utilized 
thermolysin as a model system since mammalian collagenase is at present still 
difficult to isolate. In addition thermolysin will bind to smaller peptides 
than collagenase which simplifies synthesis of inhibitors for testing. We have 
investigated three classes of compounds as metalloprotease inhibitors: phosphoramide 
hydroxamates and haloacetylamino acid derivatives. 
Phosphoramides such as Pi-Leu-Trp-OH and Pi-Leu-NH 2 have been synthesized 
and found to be excellent competitive inhibitors of thermolysin. These compounds 
are related to the microbial inhibitor phosphoramidon. The inhibitors bind 
to thermolysin due to coordination of a phosphoryl oxygen with the zinc atom of 
the enzyme. To test our proposed binding mode, Pi-Phe-OH was synthesized and 
shown to be an excellent inhibitor of carboxypeptidase. Our goal for the 
near future is to synthesize Pi-Ile-Ala-Gly-OEt, Pi-Ile-Ala-Gly-Gln-OEt and 
Pi-Ile-Ala-Gly-Gln-Arg-OEt as collagenase inhibitors. The first compound has 
already been synthesized but not yet tested with collagenase. 
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The second type of inhibitor Which we have investigated are hydroxamates 
of peptides. We have discovered that compounds such as HONH-Bzm-Ala-Gly-NH
2 (Bzm = CO7CH(CH
2 C 6 H 5 
 )C0-) are excellent competitive inhibitors of thermolysin. 
They are also quite specific and do not inhibit other proteases such as carboxy-
peptidase or chymotrypsin. We believe inhibition is due to coordination of the 
hydroxamate oxygen with the zinc atom of the enzyme. The HONH-Bzm-Ala-Gly-
moiety has been attached to agarose and has been used for the affinity chromato- 





(Ibm = isobutylmalonyl) as collagenase inhioitors. 
We are currently studying their reaction with collagenase. Jim Travis (University 
of Georgia) is supplying the collagenase. One urgent need in this area of 
research is for some decent substrates for collagenase. We are currently synthe-
sizing some. Our goal for the future is to study the kinetics of the reaction 
of the above inhibitors with collagenase. 
The final group of metalloprotease inhibitors which we have studied are 
irreversible active site directed inhibitors. Thermolysin is rapidly inhibited 





at pH 7.2. At present we are investigating the kinetics of 
these ,reactions and characterizing the site of reaction. Once the reaction 
mechanism with thermolysin is better understood, we plan to synthesize compounds 
such as C1CH
2 CON(OH)-CH(CHCH(CH 3
),)-GO-Ala-Gly-Gln-Arg-OEt and test them as an 
irreversible inhibitors of collage"nase. 
Significance. It is the belief of the author that we are approaching the 
day when synthetic protease inhibitors will be utilized clinically in the 
treatment of diseases which involve tissue destruction such as emphysema and 
arthritis. Chloromethyl ketone inhibitors of elastase are being used in various 
in vivo studies of emphysema in animal model systems. Protease inhibitors have 
proven to be valuable tools for study of the role of proteases in biological 
processes. Even if the compounds available at present only tell us that it is 
possible to treat diseases such as emphysema with inhibitors, that will be a 
major step forward since clinically useful compounds would quickly follow. 
The undersigned agrees to accept responsibility for the scientific and 
technical conduct of the project and for provision of required progress reports 
if a grant is awarded as the result of this application. 
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